New therapies to improve treatment for acute myeloid leukemia
Official title: Multi-functional cellular therapies to overcome tumor heterogeneity and limit toxicity in acute myeloid leukemia
Funded at University of California, San Francisco · NIH-10913981 · Data updated 2026-11-12
This study is exploring new ways to treat acute myeloid leukemia (AML) by using special immune cells and antibodies to create a more targeted therapy that could help patients feel better and lower the chances of the cancer coming back.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 10, 2023 |
| Project end | September 9, 2026 |
| Funding year | 2024 |
| Award (this year) | $90,988 |
| NIH project number | 5F32CA271812-02 |
| Project ID | NIH-10913981 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who are seeking new treatment options.
✕Less likely to help
Patients with other types of blood cancers or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on developing innovative cellular therapies to treat acute myeloid leukemia (AML), a type of blood cancer with a low survival rate. The approach aims to address two major challenges in AML treatment: the lack of specific targets for therapy and the variability of the cancer cells within patients. By utilizing advanced technologies, including engineered T-cells and bispecific antibodies, the research seeks to create a more effective treatment that minimizes side effects and improves patient outcomes. Patients may benefit from a therapy that targets the cancer more precisely and reduces the risk of relapse.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with acute myeloid leukemia.
How similar studies have gone: Other research has shown promising results with similar cellular therapy approaches in treating blood cancers, indicating potential for success in this area.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Kasap, Corynn — University of California, San Francisco
- Study coordinator: Kasap, Corynn
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.